Mizuho raised the firm’s price target on Immuneering (IMRX) to $12 from $10 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Two new option listings and three option delistings on October 2nd
- Immuneering’s Promising Phase 2a Data and Safety Profile Drive Buy Rating
- Immuneering Announces Public Offering to Raise $164.1M
- Immuneering price target raised to $30 from $21 at Oppenheimer
- Immuneering 18.96M share Spot Secondary priced at $9.23